O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes

Exp Mol Med. 2005 Jun 30;37(3):220-9. doi: 10.1038/emm.2005.30.

Abstract

It has been known that O-linked beta-N-acetylglucosamine (O-GlcNAc) modification of proteins plays an important role in transcription, translation, nuclear transport and signal transduction. The increased flux of glucose through the hexosamine biosynthetic pathway (HBP) and increased O-GlcNAc modification of protein have been suggested as one of the causes in the development of insulin resistance. However, it is not clear at the molecular level, how O-GlcNAc protein modification results in substantial impairment of insulin signaling. To clarify the association of O-GlcNAc protein modification and insulin resistance in rat primary adipocytes, we treated the adipocytes with O-(2-acetamido-2deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc), a potent inhibitor of O-GlcNAcase that catalyzes removal of O-GlcNAc from proteins. Prolonged treatment of PUGNAc (100 microM for 12 h) increased O-GlcNAc modification on proteins in adipocytes. PUGNAc also drastically decreased insulin-stimulated 2-deoxyglucose (2DG) uptake and GLUT4 translocation in adipocytes, indicating that PUGNAc developed impaired glucose utilization and insulin resistance in adipocytes. Interestingly, the O-GlcNAc modification of IRS-1 and Akt2 was increased by PUGNAc, accompanied by a partial reduction of insulin-stimulated phosphorylations of IRS-1 and Akt2. The PUGNAc treatment has no effect on the expression level of GLUT4, whereas O-GlcNAc modification of GLUT4 was increased. These results suggest that the increase of O-GlcNAc modification on insulin signal pathway intermediates, such as IRS-1 and Akt2, reduces the insulin-stimulated phosphorylation of IRS-1 and Akt2, subsequently leading to insulin resistance in rat primary adipocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylglucosamine / analogs & derivatives*
  • Acetylglucosamine / metabolism
  • Acetylglucosamine / pharmacology
  • Adipocytes / metabolism*
  • Animals
  • Deoxyglucose / pharmacokinetics
  • Glucose Transporter Type 5
  • Glycosylation
  • Immunoprecipitation
  • Insulin Receptor Substrate Proteins
  • Insulin Resistance*
  • Male
  • Monosaccharide Transport Proteins / metabolism
  • Oximes / pharmacology*
  • Phenylcarbamates / pharmacology*
  • Phosphoproteins / metabolism*
  • Phosphorylation
  • Protein Serine-Threonine Kinases / metabolism*
  • Proto-Oncogene Proteins / metabolism*
  • Proto-Oncogene Proteins c-akt
  • Rats
  • Rats, Sprague-Dawley
  • Subcellular Fractions / metabolism
  • beta-N-Acetylhexosaminidases / antagonists & inhibitors

Substances

  • Glucose Transporter Type 5
  • Insulin Receptor Substrate Proteins
  • Irs1 protein, rat
  • Monosaccharide Transport Proteins
  • Oximes
  • Phenylcarbamates
  • Phosphoproteins
  • Proto-Oncogene Proteins
  • N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime
  • Deoxyglucose
  • Akt2 protein, rat
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt
  • beta-N-Acetylhexosaminidases
  • Acetylglucosamine